FDA Commissioner Marty Makary spent hours over the weekend at Rick Pazdur’s house trying to convince the agency’s longtime cancer chief to step up to the role of top drug regulator, a source familiar with …
Roche places a $1bn bet on C4T degrader-antibody conjugates
Roche is paying $20 million upfront to secure rights to two degrader-antibody conjugates (DACs) for cancer developed by longtime partner C4T.


